#### Form 144 Filer Information UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

# **144: Filer Information**

Filer CIK0001965622Filer CCCXXXXXXXIs this a LIVE or TEST Filing?IVE TESTSubmission Contact InformationIVE

Name Phone E-Mail Address

## **144: Issuer Information**

Name of IssuerAscendis Pharma A/SSEC File Number001-36815Address of IssuerTUBORG BOULEVARD 12<br/>HELLERUP<br/>DENMARK<br/>DK-2900Phone45 70 22 22 44Name of Person for Whose Account the Securities are To Be SoldJENSEN MICHAEL WOLFF

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

**144: Securities Information** 

| Title of the Class of<br>Securities To Be Sold | Name and Address of<br>the Broker   | Number of<br>Shares or<br>Other Units<br>To Be Sold | Aggregate<br>Market<br>Value |          | Approximate<br>Date of Sale | SACHPITIAG |
|--|---|---|------------------------------|----------|-----------------------------|------------|
| American Depository<br>Shares (ADSs)           | Citigroup Global Markets<br>Inc.<br>390 Greenwich Street<br>New York NY 10013 | 927   | 87147.27                     | 57328548 | 05/05/2023                  | NasdaqGS   |

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

# **144: Securities To Be Sold**

| Title of the<br>Class | • | Nature of<br>Acquisition | Name of<br>Person from |          | Amount of<br>Securities | Nature of<br>Payment * |
|-----------------------|---|--------------------------|------------------------|----------|-------------------------|------------------------|
|                       |   | Transaction              |                        | Acquired | Acquired                |                        |

Officer

|      |   | Whom<br>Acquired       | a<br>Gift? |     |                              |
|------|---|------------------------|------------|-----|------------------------------|
| ADSs | 12/09/2022 Restricted Stock<br>Unit Vesting | Ascendis<br>Pharma A/S |            | 927 | 12/09/2022 Services Rendered |

\* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

# 144: Securities Sold During The Past 3 Months

Nothing to Report **I** 

#### 144: Remarks and Signature

Remarks Date of Notice *ATTENTION:* 

05/05/2023

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)